ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$58.98
+1.65%Price chart
Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26
Key dataOct 26, 2026
Open$58.43
From 52W high−34.17%
Volume979755.00
Market cap$8.33B
P/E (TTM)—
P/S (TTM)12.4x
Div yield—
Key dataOct 26, 2026
Open
$58.43
From 52W high
−34.17%
Volume
979755.00
Market cap
$8.33B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−56.8x
P/E (TTM)
—
RSI (14)
33.1
MomentumView details →
1D Return
+1.65%
YTD Return
−12.59%
SummaryUpdated Jun 1, 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a clinical-stage biotechnology company founded in 1989 and headquartered in Pasadena, California. The company went public in 1993 and has evolved into a leading developer of RNA interference (RNAi) therapeutics for treating rare and complex diseases. Arrowhead has built a proprietary platform technology that enables targeted delivery of RNAi medicines to specific tissues and organs, with a robust pipeline spanning multiple therapeutic areas including cardiometabolic diseases, pulmonary disorders, muscular dystrophy, and central nervous system conditions.
Similar companies
Latest newsMore news →
Arrowhead Pharmaceuticals announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, its first investigational dual-functional RNAi therapeutic for mixed hyperlipidemia.42d agoArrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026 in Munich, showing reduced acute pancreatitis events in patients with severe hypertriglyceridemia.58d agoArrowhead Pharmaceuticals announced it will present new clinical data for plozasiran at the European Society of Cardiology Congress in Munich, Germany, on August 30, 2026.64d ago